10:53 AM EDT, 06/03/2026 (MT Newswires) -- Medtronic ( MDT ) reported better-than-expected fiscal fourth-quarter results on Wednesday, while the medical-device maker projected earnings and organic revenue growth for the current year.

In the three months ended April 24, adjusted earnings fell to $1.55 a share from $1.62 a year earlier, topping the consensus of $1.54 in a FactSet survey. Revenue rose 9.9% to $9.81 billion, above analysts' estimate of $9.62 billion. On an organic basis, excluding currency and other items, sales gained 6.6%.

Medtronic ( MDT ) shares climbed 4.9% in Wednesday trading and are down 19% this year.

"We are pleased to have delivered results ahead of expectations on both revenue and EPS," Chief Financial Officer Thierry Pieton said in a statement. "As we look to (fiscal 2027), we are entering the year with strong momentum, a resilient operating foundation, and a clear path to deliver durable growth."

For fiscal 2027, the company expected adjusted EPS of $5.90 to $6, reflecting growth of 6.7% to 8.5%. Analysts project EPS of $6.05. The company said foreign exchange should have a neutral to 1% accretive impact.

Medtronic ( MDT ) expects organic revenue to rise 6.8% to 7.3% for the full year, compared with 5.8% growth in fiscal 2026.

Revenue in the cardiovascular portfolio climbed 14% to $3.8 billion in the fourth quarter, buoyed by a 22% increase in cardiac rhythm and heart-failure products. Neuroscience sales rose 5% to $2.75 billion, and medical surgical revenue advanced 8% to $2.39 billion. Diabetes revenue climbed 15% to $837 million, supported by growth in insulin-pump and sensor technologies.

CEO Geoff Martha said the company continued to see strength across major businesses, including cardiac rhythm management, cranial and spinal technologies, and surgical, and is building momentum in its highest-growth opportunities.

Price: 77.37, Change: +3.62, Percent Change: +4.91